Daraxonrasib

Early-stage combination data from Boston-based Tango Therapeutics (Nasdaq: TNGX) reported a 92% objective response rate for vopimetostat, its oral MTA-cooperative PRMT5 inhibitor, combined with Revolution Medicines’ (Nasdaq: RVMD) daraxonrasib in patients with MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma — a signal that, if confirmed in randomized studies, could support a chemotherapy-free precision approach in a disease where cytotoxic regimens have long defined the standard of care. Vopimetostat exploits synthetic lethality in MTAP-deleted tumors, where accumulation of methylthioadenosine sensitizes cancer cells to PRMT5 inhibition; combining this mechanism with RAS(ON) suppression via daraxonrasib is designed to deliver deeper and more durable responses in the roughly 40% of pancreatic cancers harboring MTAP deletion. Daraxonrasib is Revolution Medicines’ pan-RAS(ON) inhibitor, designed to suppress active RAS signaling regardless of the specific KRAS mutation, and recently became one of the most closely watched pancreatic cancer programs after demonstrating an overall survival benefit in the Phase III RASolute 302 study. Trial data The data derive from an ongoing Phase I/II study evaluating vopimetostat-based combinations in MTAP-deleted, RAS-mutant solid tumors. As of a May 28, 2026 cutoff, 20 PDAC patients had been enrolled in the daraxonrasib arm; 12 were response-evaluable with at least 14 weeks of follow-up. Among these, 11 of 12 achieved an objective response (92% ORR), with 9 of 11 responses confirmed. A 100% disease control rate and a 90% six-month progression-free survival rate were also reported, with median PFS not yet reached. The patient population was heavily pretreated — more than half received the combination as third-line therapy — and 70% had liver metastases, underscoring the challenging clinical context. Three of five evaluable NSCLC patients also responded (100% ORR), though numbers remain too small for meaningful interpretation. The combination was generally well tolerated at both dose levels tested (vopimetostat 200 mg or 250 mg plus daraxonrasib 100 mg once daily). Most adverse events were Grade 1 or 2; rash, stomatitis/mucositis, and diarrhea were the most common treatment-related events. Three dose-limiting toxicities were observed in two patients at the higher vopimetostat dose level, including Grade 3 rash and Grade 3 stomatitis with fatigue. No Grade 4 or 5 treatment-related adverse events and no discontinuations due to adverse events were reported. Competitive context The data arrive days after Revolution Medicines presented Phase III RASolute 302 results showing daraxonrasib monotherapy nearly doubled median overall survival versus chemotherapy in previously treated PDAC — validating the RAS(ON) backbone that Tango is now combining with PRMT5 inhibition. The vopimetostat plus daraxonrasib ORR of 92% in heavily pretreated patients is numerically higher than the 33% ORR reported for daraxonrasib monotherapy in RASolute 302, though cross-trial comparisons are limited by differences in study design, patient selection, and the early, uncontrolled nature of the combination data. Amgen’s AMG 193, another MTA-cooperative PRMT5 inhibitor, represents the most direct competitive overlap in the MTAP-deleted PDAC space. Tango plans to finalize the design of a Phase III randomized-controlled trial in first-line MTAP-deleted pancreatic cancer in H2 2026, with vopimetostat monotherapy lung cancer data and initial TNG456 glioblastoma data also expected in H2 2026. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

iStock, bpawesome After Revolution Medicine’s groundbreaking data drop in April, its Tango-partnered combination approach has demonstrated what analysts called “unprecedented” results for 12 patients with pancreatic cancer, teeing up a late-stage study. Tango Therapeutics’ experimental PRMT5 inhibitor combined with Revolution Medicines’ RAS inhibitor achieved a 92% response rate in pancreatic cancer, a greater response than either have seen as monotherapies or in combination with chemotherapy. “WOW!” Leerink Partners wrote in a Monday note forecasting Tango’s stock to at least double on the data. Sure enough, the biotech’s share price rose 43% as the markets opened Monday to $28.94. RevMed, which is up 88% year to date, rose just under 1% to $150.62. “The results from our ongoing combination trial dramatically exceeded our expectations,” Tango CEO Malte Peters said on a Monday investor call. Given the data, Tango is queuing up registrational trial plans for the combination strategy in the front-line setting. The findings come from an ongoing Phase 1/2 study of Tango’s vopimetostat and either RevMed’s zoldonrasib or daraxonrasib for patients with advanced MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC). Earlier this year, RevMed’s daraxonrasib alone doubled survival to 13.2 months in PDAC compared to chemotherapy, stunning the field in a disease that carries a 13% survival rate five years after diagnosis. Now, Tango has topped that, sharing data from a dose-escalation arm in which patients every day received either vopimetostat 200 mg or 250 mg, plus daraxonrasib 100 mg. Of 12 PDAC patients with 14 weeks of follow up, 92% (11 patients) saw an objective response rate, with nine confirmed responses. The data also demonstrated 100% disease control rate for the 12 patients, plus a 90% six-month progression-free survival (PFS) rate. “The efficacy results speak for themselves,” Leerink Partners analysts wrote, underscoring “unprecedented activity” in the second-line setting and suggesting “strong synergy” between the paired agents in both response rate and durability. Pancreatic cancer Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve on that result with increased tolerability—and more time for patients. May 18, 2026 · 7 min read · Heather McKenzie Read more When considering the three evaluable patients with NSCLC, 100% achieved an objective response rate at a minimum of 14 weeks follow up. While “encouraging,” Leerink analysts said the data were “still too limited in scope,” to forecast longer-term success. The combination of vopimetostat and zoldonrasib achieved a 52% ORR with 14 patients responding and a 74% PFS rate. In terms of safety, Tango said the investigational combination approach was generally well-tolerated, with no new safety signals reported. Zero patients discontinued treatment because of adverse events, and no grade 4 or 5 events occurred. The 100-mg daraxonrasib dose is lower than RevMed’s monotherapy level of 300 mg and chemo combo of 200 mg, which could suggest a possible drug interaction or overlapping toxicities, Leerink noted. Tango now hopes to speed into Phase 3 development in first-line MTAP-deleted pancreatic cancer and indicated that it would consider moving forward in second-line treatment as well, pending regulatory feedback. “Given the unprecedented activity seen in PDAC, a terminal disease with limited treatment options, we think the FDA would be hard-pressed to deny such a request,” Leerink wrote. Pancreatic cancer ASCO: Revolution poised to capture RAS space as pancreatic cancer dataset ‘derisks’ approval Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology’s annual meeting this weekend, as Truist Securities predicts a possible third quarter launch for the pancreatic cancer drug. June 1, 2026 · 3 min read · Brianna Abbott Read more